But in an interview with The Wall Street Journal this week, Anderson said the company couldn’t be distracted from the tough restructuring to fix the businesses. And the abandoned clinical trial dashed hopes Bayer had found a successor to lucrative drugs whose patents are expiring soon. After joining Bayer, the Texas native appointed a team of experts including investment bankers to map out potential breakup scenarios. The team studying strategic options is looking at how spinning off some operations would affect the company, Anderson said. During an analyst call this week, Bayer said it had settled 113,000 glyphosate cases in the U.S. from an original list of 165,000.

Source: Wall Street Journal November 25, 2023 17:42 UTC